Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of DAT-2645 in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DNA Damage Repair Pathway

NCT06614751 is registered in ClinicalTrials.gov with Danatlas Pharmaceuticals Co., Ltd as lead sponsor.

NCT NCT06614751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06614751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of DAT-2645 in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DNA Damage Repair Pathway
Lead sponsor
Danatlas Pharmaceuticals Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 1, 2024
Completion date
June 1, 2027
Enrollment
112 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, brca mutation, breast cancer, colorectal cancer, endometrial cancer, gastric cancer, hrd cancer, metastatic solid tumors, pancreatic cancer, prostate cancer, solid cancers